A Randomized, Double-blinded and Placebo-controlled Multicenter Phase IIb Clinical Trial to Evaluate the Efficacy and Safety of Gantong Granules in the Treatment of Common Cold (Wind-Heat Syndrome)

Gantong Granules in the Treatment of Common Cold (Wind-Heat Syndrome): a Randomized, Double-blinded and Placebo-controlled Multicenter Clinical Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004255

Enrollment

Unknown

Registered

2014-01-10

Start date

2014-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common Cold

Interventions

low-dose group:Gantong granules 5g Tid and placebo granules 10g T

medial-dose group:Gantong granules 10g Tid and placebo granules 5g T

high-dose group:Gantong granules 15g Tid

placebo:Placebo 15g Tid

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Meet the western medicine diagnostic criteria for the common cold; 2. Meet Chinese medcine symptoms and signs of Wind-Heat syndrome; 3. Aged 18 to 65 years old; 4. Duration is no more than 48 hours; 5. Willing to participate and sign the inform consent.

Exclusion criteria

Exclusion criteria: 1. Influenza, acute bacterial sinusitis, allergic rhinitis, streptococcal pharyngitis and herpangina; 2. Have found that lung radiographic shadows or signs of pulmonary infection; 3. Patients with a serious primary cardiovascular,pumonary, kidney, and hematological diseases; 4. Index of liver function (ALT, AST, STB, ALP, Y-GT) is 1.5 times higher than normal level, abnormal serum creatitine, urine protein>+, white blood cell count10*10^9/L,and/or N>80%; 5. Patients who used drugs to treat the common cold; 6. Body temperature higher than 38.5 degree C; 7. Pregnant or lactating women, or women who have birth plan; 8. Allergic constitution or be allergy to the drug composition used in the trial; 9. mental illness; 10. Patients who is participating or participated in last 3 months in other drug clinical trials;11.Patients who ie not suitable to participate in the clinical trials.

Design outcomes

Primary

Measure	Time frame
The primary end point was all symptom duration;main symptom duration;TCM primary symptom duration;body temperature return to normal time;Effects of common cold;Effects of TCM symptoms;	—

Countries

China

Contacts

Public ContactMao Bing

West China Hospital, Sichuan University

maobing@medmail.com.cn+86 18980601724

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 4, 2026